An observational study in Obesity and Hypertension, sponsored by Beijing Friendship Hospital. Active, not recruiting at 1 site in China. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-02.
Sponsored by Beijing Friendship Hospital · Observational
Long-term Impact of Overweight/Obesity and Hypertension on Cardiovascular Risk in Middle-aged and Elderly Adults
Overweight and obesity are major risk factors associated with the development of hypertension, poor blood pressure control, and adverse cardiovascular outcomes. However, evidence regarding the long-term impact of overweight/obesity and hypertension on cardiovascular risk in middle-aged and elderly populations remains limited. Therefore, the present study aims to evaluate the long-term effects of overweight/obesity and hypertension on cardiovascular risk in middle-aged and elderly adults.Additionally, a subgroup analysis will be conducted in participants with sarcopenia to assess the influence of blood pressure on prognosis, exploring potential interactions between muscle loss, hypertension, and cardiovascular outcomes.
6,297 studies on the registry are indexed under Obesity; 1,693 are open to participants now.
This study's enrollment of 31,080 is above the median of 135 across 1,283 observational studies indexed under Obesity.
Browse Obesity studies →Beijing Friendship Hospital is the lead sponsor of 216 studies on the registry; 95 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults undergoing routine physical examinations at community health service centers in Tongzhou, China.
Exclusion Criteria:
Patients who were diagnosed with obesity (body mass index (BMI)≥28kg/m2) and hypertension (systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥ 140/90 mmHg).
Other: No intervention
Overweight patients (24 kg/m2≤BMI≤28 kg/m2) diagnosed with hypertension (SBP/DBP≥140/90 mmHg).
Other: No intervention
Lean patients (BMI ≤ 24 kg/m2) diagnosed with hypertension (SBP/DBP ≥ 140/90 mmHg).
Other: No intervention
Lean patients (BMI ≤ 24 kg/m2) diagnosed with normotensive (SBP/DBP \< 140/90 mmHg).
Other: No intervention
Overweight patients (24 kg/m2≤BMI≤28 kg/m2) diagnosed with normotensive (SBP/DBP\<140/90 mmHg)
Other: No intervention
Patients who were diagnosed with obesity (BMI≥28kg/m2) and normotensive (SBP/DBP\<140/90 mmHg).
Other: No intervention
This is an observational study without any intervention
Percentage of participants with major adverse cardiovascular events (MACEs)
Percentage of participants with major adverse cardiovascular events (MACEs), including all-cause death, nonfatal myocardial infarction (MI), nonfatal stroke and coronary revascularization.
Time frame: 2021-2026
Percentage of participants with all-cause death
Percentage of participants with cardiovascular, non-cardiovascular and undetermined death.
Time frame: 2021-2026
Percentage of participants with MI
Percentage of participants with fatal and nonfatal MI.
Time frame: 2021-2026
Percentage of participants with stroke
Percentage of participants with fatal and nonfatal stroke.
Time frame: 2021-2026
Percentage of participants undergoing coronary revascularization
Percentage of participants undergoing ischemia- and non-ischemia-driven coronary revascularization.
Time frame: 2021-2026
Change in BP control rate
Change in BP control rate (office BP: SBP \< 140 mmHg and DBP \< 90 mmHg) from baseline to follow-up.
Time frame: 2021-2026
Change in SBP
Change in SBP from baseline to follow-up.
Time frame: 2021-2026
Change in estimated glomerular filtration rate (eGFR)
Change in estimated glomerular filtration rate (eGFR) in ml/min/1.73m2 from baseline to follow-up.
Time frame: 2021-2026
Change in low-density lipoprotein-cholesterol (LDL-c)
Change in low-density lipoprotein-cholesterol (LDL-c) in mmol/L from baseline to follow-up.
Time frame: 2021-2026
Percentage of participants with Metabolic dysfunction-associated steatotic liver disease (MASLD)
Percentage of participants with Metabolic dysfunction-associated steatotic liver disease.
Time frame: 2021-2026
Plan to share: No
This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Friendship Hospital